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Abstract 
Background: Proton pump inhibitor (PPI) use was reportedly associated with an excess of 
adverse cardiovascular (CV) events, thus making their systemic effects relevant to public health. 
PPIs reduce gastric acid secretion, causing increased gastrin release. Gastrin stimulates β-cell 
neogenesis and enhances insulin release, exerting an incretin-like effect. Our aim was to assess, if 
PPI usage is associated with altered glycaemia in patients with CV disease.  
Methods: We retrospectively analyzed medical records of 102 subjects (80 with ischemic heart 
disease) who underwent a routine oral glucose tolerance test while hospitalized in a cardiology 
department. Fasting and 2-h postload glucose levels were compared according to PPI use for ≥1 
month prior to admission.  
Results: Compared to 51 subjects without PPIs, those on a PPI were older, more frequently male, 
had a lower body-mass index and a tendency to a worse renal function. PPI users and non-users 
exhibited similar glucose levels at baseline (5.6 ± 0.9 vs. 5.5 ± 1.1 mmol/l, P = 0.5) and 2-hrs post 
glucose intake (9.8 ± 3.0 vs. 9.9 ± 3.4 mmol/l, P = 0.9). This was consistent across subgroups 
stratified by gender or diabetes status. The results were substantially unchanged after adjustment 
for different characteristics of subjects with and without PPIs.  
Conclusions: PPI use does not appear associated with altered glycaemia in subjects with CV 
disease. Unchanged glucose tolerance despite PPI usage may result from simultaneous activation of 
pathways that counteract the putative PPI-induced incretin-like effect. 
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Introduction 
Proton pump inhibitors (PPIs) are among the 
most prescribed drugs worldwide. PPIs use was 
reportedly associated with an excess of adverse 
cardiovascular (CV) events, thus making their 
systemic effects relevant to public health. This 
association was described in various study groups, 
including post-myocardial infarction patients on 
clopidogrel in addition to aspirin [1] or regardless of 
clopidogrel use [2], and even in general population 








Therefore, it can be hypothesized that an elevated risk 
of myocardial infarction in patients taking PPIs might 
– at least in part – result from yet unknown 
mechanisms not directly involving platelet 
aggregation, and unrelated to putatively abnormal 
absorption of antiplatelet drugs. Thus, of clinical 
relevance is the investigation of potential novel 
pathways which may contribute to systemic PPIs 
effects. 
Gastrin is released from antro-duodenal G cells 
in response to a meal and stimulates gastric acid 
secretion by the parietal cells of the stomach. Gastrin 
release is inhibited by a low pH via negative feedback, 
so gastrin release is increased in PPI users. Gastrin 
also acts on pancreatic β-cells: stimulates β-cell 
growth and neogenesis [4] and enhances 
glucose-stimulated insulin release, i.e. exerts an 
incretin-like effect [5].  
The incretin effect, ascribed mainly to 
glucagon-like peptide 1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP), 
has re-gained attention in recent years, which was 
associated with the introduction of incretin 
hormones-based therapies in diabetes [6]. Of note, 
over 40 years ago it was demonstrated that gastrin 
was able to produce an incretin-like effect at 
physiological levels [5] that are similar to the degree 
of chronic hypergastrinemia reported in PPI users [7]. 
A novel GLP-1–gastrin dual agonist improved 
glucose homeostasis in experimental models of 
obesity and diabetes with the reference to a GLP-1 
receptor agonist alone [8–10]. However, clinical 
studies on the hypothetical ability of PPI to improve 
glucose tolerance brought inconsistent results [11]. 
Moreover, these investigations were largely focused 
on glycemic control in subjects with type 2 diabetes. 
Of note, subjects with elevated glucose levels below 
the diabetic threshold also exhibit a higher risk of CV 
mortality [12] and predisposing abnormalities [13]. 
Thus, our aim was to estimate, if PPI use is 
associated with lower fasting or postload glycaemia in 
patients with cardiovascular disease.  
Materials and Methods 
Patients 
We retrospectively analyzed medical records of 
102 patients (62 men and 40 women; mean age, 66 ± 10 
years) without a previous history of established 
diabetes hospitalized in a cardiology department who 
underwent a 75-g oral glucose tolerance test (OGTT) 
as a routine diagnostic test prior to discharge. 
Exclusion criteria included severe renal insufficiency 
(estimated glomerular filtration rate [GFR] below 30 
ml/min per 1.73 m2 by the Modification of Diet in 
Renal Disease [MDRD] study equation), 
hemodynamic instability, severe respiratory 
insufficiency, anemia and other significant coexistent 
diseases or relevant abnormalities in routine 
laboratory analyses. All patients were receiving a 
standard medication in accordance with current 
practice guidelines. 
Fasting and 2-h postload glucose levels were 
compared according to PPI use for ≥1 month before 
admission. Additionally, the analysis was repeated 
for the study patients stratified by gender and 
diabetes status. Diabetes and other glucose tolerance 
categories were defined in agreement with the 2003 
recommendations of the American Diabetes 
Association [14] on the basis of the results of the 
OGTT performed during the index hospitalization.  
The ethics committee of our university approved 
the study protocol and the fact that informed consent 
was not sought owing to a retrospective study design 
(Approval number: 122.6120.228.2016).  
Statistical Analysis  
Data are shown as mean and standard deviation 
(SD) or numbers (n) and percentages. Clinical 
characteristics of the study subjects were compared 
between PPI users and non-users by means of a 
2-tailed Student’s t-test for continuous variables and 
Fisher’s exact test for categorical data. The study 
design allowed to detect a difference in glycaemia 
between PPI users and non-users of about 0.55 SD – 
i.e. 0.5 mmol/l for fasting glycaemia and 1.7 mmol/l 
for 2-h postload glucose – with a power of 80% at a 
type I error rate of 0.05. In order to adjust for different 
characteristics of patients with and without PPI, 
analysis of covariance (ANCOVA) was done with 
glycaemia as a dependent variable and characteristics 
for which the intergroup P value was <0.15 as 
covariates. A P value below 0.05 was considered 
significant. The analyses were performed using 
STATISTICA (data analysis software system), version 
12 (StatSoft, Inc., Tulsa, OK, USA).  
Results 
Our study group consisted of 102 subjects, with a 
discharge diagnosis of ischemic heart disease in 80 
patients (78%) and heart failure in 26 patients (25%). 
By means of an OGTT performed during the index 
hospitalization, normal glucose tolerance was 
confirmed in 25 patients (24%), whereas impaired 
fasting glucose (IFG) or impaired glucose tolerance 
(IGT) were detected in 42 subjects (41%). In addition, 
in 35 subjects (34%) type 2 diabetes was diagnosed on 
the basis of the OGTT.  
Compared to 51 subjects without PPIs, those on a 
PPI (mostly omeprazole 20 mg o.i.d. or pantoprazole 




20 mg o.i.d.) were older (69 ± 9 vs. 64 ± 10 years, P = 
0.004), more frequently male (71 vs. 51%, P = 0.07), 
had a lower body-mass index (BMI) (26.9 ± 3.4 vs. 29.3 
± 4.9 kg/m2, P = 0.006) and a tendency to worse renal 
function (GFR: 71 ± 19 vs. 76 ± 17 ml/min per 1.73 m2, 
P = 0.13) (Table 1).  
 
Table 1. Selected clinical characteristics of the study subjects 
according to PPI use prior to admission. 





Age, years 69 ± 9 64 ± 10 0.004 
Men, n (%) 36 (71) 26 (51) 0.07 
IFG or IGT, n (%) 25 (49) 17 (33) 0.16 
Newly-diagnosed diabetes, n 
(%) 
17 (33) 18 (35) 0.9 
Body mass index, kg/m2 26.9 ± 3.4 29.3 ± 4.9 0.006 
GFR, ml/min per 1.73 m2 71 ± 19 76 ± 17 0.13 
Systolic blood pressure, mmHg 134 ± 17 133 ± 15 0.6 
Data are shown as mean ± SD or n (%) 
aBy 2-tailed Student’s t-test or Fisher’s exact test for continuous and categorical 
data, respectively. 
Abbreviations: GFR: estimated glomerular filtration rate; IFG: impaired fasting 




PPI users and non-users exhibited similar 
glucose levels at baseline (5.6 ± 0.9 vs. 5.5±1.1 mmol/l, 
P = 0.5) and 2-hrs post glucose intake (9.8 ± 3.0 vs. 9.9 
± 3.4 mmol/l, P = 0.9) (Table 2, Figure 1). This was 
consistent across subgroups categorized by gender 
and diabetes status (Table 2, Figure 2 A-B). The 
adjustment for age, BMI and GFR by ANCOVA did 
not substantially change the results. 
 
Table 2. Fasting and 2-h postload glucose according to PPI use 
prior to admission. 
 Fasting glucose (mmol/l)  





All study subjects, n=102 5.6 ± 0.9 5.5 ± 1.1 0.5 
Gender 
 Men, n=62 
 Women, n=40 
 
5.7 ± 0.9 
5.5 ± 0.9 
 
5.3 ± 0.6 





 No diabetes, n=67 
 Newly-diagnosed diabetes, 
n=35  
 
5.5 ± 0.8 
5.9 ± 0.9 
 
5.2 ± 0.6 




 2-h postload glucose (mmol/l)  
 PPI users PPI non-users P value 
All study subjects, n=102 9.8 ± 3.0 9.9 ± 3.4 0.9 
Gender 
 Men, n=62 
 Women, n=40 
 
9.8 ± 3.0 
9.9 ± 3.1 
 
9.4 ± 2.7 





 No diabetes, n=67 
 Newly-diagnosed diabetes, 
n=35  
 
8.2 ± 1.8 
13.2 ± 2.2 
 
7.9 ± 2.3 




Data are shown as mean ± SD; P values by 2-tailed Student’s t-test. 
Abbreviations as in Table 1. 
 
Discussion 
Our study showed no association between PPI 
use and fasting or postload glycaemia in patients with 
CV disease irrespective of diabetes status.  
 
 
Figure 1. Glycaemia during a 75-g oral glucose tolerance test according to PPI use – all study subjects. 





Figure 2. Glycaemia during a 75-g oral glucose tolerance test (OGTT) according to PPI use – patients stratified by diabetes status: (A) subjects without diabetes; (B) 
subjects with newly-diagnosed type 2 diabetes detected on the basis of the OGTT. 
 
Comparison with previous reports 
To the best of our knowledge, the effect of PPI on 
glucose levels in non-diabetic subjects was previously 
assessed in only one study [15] that reported lower 
fasting glycaemia and higher concentrations of insulin 
after 12 weeks of pantoprazole administration in 38 
healthy volunteers. In our hands, chronic PPI use was 
unrelated to glucose levels – either fasting or 2-h 
postload. Thus, our negative result adds to a 
controversy about the effect of chronic PPI use on 
glucose tolerance. Both positive and negative results 
were published with regard to the ability of PPI usage 
to affect glycemic control in patients with type 2 
diabetes. This was found for cross-sectional 
retrospective studies [16–20] and randomized, 
double-blind, placebo-controlled studies [21–23].  





The rationale for the previous studies [15–23] 
and our retrospective analysis was the previously 
demonstrated incretin-like effect of gastrin [5], which 
was shown at circulating gastrin concentrations that 
were comparable to those reported in long-term PPI 
users [7]. Admittedly, gastrin is without effect on 
basal insulin secretion and small rises in gastrinemia 
on oral glucose challenge are unlikely to affect the 
non-glycemic insulin release under these conditions 
[5, 24]. However, peptides and amino acids are a 
much more potent stimulus for gastrin release. It is 
noteworthy that the incretin-like effect of gastrin 
(reflected by an almost 2-fold higher integrated 
insulin response) was demonstrated upon synthetic 
human gastrin-17 infusion at the lowest dose which 
increased circulating gastrin by the same order of 
magnitude as those observed for maximal 
concentrations of endogenous gastrin (about 3-fold) 
after a protein-rich meal [5].  
In addition, interactions with other hormones 
may contribute to effects of gastrin on glucose 
metabolism. Gastrin stimulates GLP-1 secretion by 
intestinal L cells [25] and down-regulates the release 
of ghrelin [26], the “hunger hormone” that also 
inhibits insulin secretion in the islets [27]. Moreover, 
joint GLP-1 and gastrin receptor coactivation 
ameliorated glucose homeostasis and induced a more 
profound increase in insulin response and β-cell mass 
compared to GLP-1 agonism alone in animal models 
of diabetes [8–10, 28]. Finally, in diabetic mice these 
metabolic effects were mimicked by combination 
therapy with a GLP-1 receptor agonist and a PPI, 
which was associated with an over 2-fold increase in 
endogenous gastrin levels [29].  
Unchanged glucose tolerance despite PPI usage 
may result from simultaneous activation of pathways 
that counteract the PPI-induced incretin-like effect of 
gastrin. First, because gastrin stimulated both insulin 
and glucagon secretion in anesthetized dogs [30] and 
in isolated, perfused canine pancreas [31], higher 
levels of gastrin on chronic PPI therapy may enhance 
not only insulin but also glucagon release that could 
oppose the glucose-decreasing effect of insulin. 
Second, PPIs lowered the formation of nitric oxide 
(NO), an endogenous ubiquitous mediator, via 
potentiated accumulation of the endogenous NO 
synthesis inhibitor asymmetric dimethylarginine 
(ADMA) in human cultured microvascular 
endothelial cells, blunted endothelium-dependent 
relaxation in murine aortic rings ex vivo, and increased 
circulating ADMA in mice [32]. Since a report based 
on OGTT and hyperglycemic clamps in healthy 
subjects administered L-NG-nitroarginine methyl 
ester, an inhibitor of NO synthesis, suggested that 
endogenous NO might enhance the 
glucose-dependent insulin release and reduce insulin 
clearance [33], the PPI-induced NO deficiency – if 
clinically confirmed – could hypothetically attenuate 
the incretin-like effect of hypergastrinemia associated 
with PPI use. On the other hand, the notion of 
endogenous NO as a modulator of glucose 
homeostasis [34] comes from experimental studies 
whose results cannot be simply extrapolated into 
clinical conditions [33, 35]. In particular, 
L-NG-nitroarginine methyl ester may affect glycaemia 
also via adrenal epinephrine release [36], and the 
inhibition of the insulin-degrading enzyme through 
S-nitrosylation was demonstrated only in vitro at high 
concentrations of artificial putative NO donors and 
consequent exposure to supraphysiological levels of 
NO liberated from these compounds [35]. Moreover, 
in a recent clinical observational study [37], we did 
not confirm the PPI–ADMA interaction.  
The incretin effect is defined as insulin-releasing 
activity of gut hormones, which explains a higher 
insulin response to oral than intravenous glucose at 
an equivalent level of glycaemia [38–40]. This term 
was launched in 1929 to explain the ability of upper 
gut extracts to lower glycaemia, presumably via a 
higher insulin secretion (INtestine seCRETtion 
INsulin) [41]. According to current views, the incretin 
effect is linked predominantly to GLP-1 and GIP [6, 
42, 43], both of which are degraded by the widely 
expressed dipeptidyl peptidase IV (DPP-4). GLP-1 
stimulates the glucose-induced insulin secretion, 
inhibits glucagon release and delays gastric emptying, 
all of which contribute to glucose lowering [43]. The 
translation of the knowledge of incretin biology has 
led to the development of GLP-1 receptor agonists 
and DPP-4 inhibitors as hypoglycemic agents. 
Recently, extraglycemic effects of the classical 
incretin GLP-1 were reported, including vasodilation 
and prevention of post-ischemic myocardial 
dysfunction and injury [44, 45]. Of note, 
cardioprotection was also induced by a metabolically 
inactive product of GLP-1 breakdown [46]. Whether 
chronic elevations of circulating gastrin in patients 
taking a PPI may also exert an influence on the heart 
and vasculature is unknown.  
Study limitations 
First, we performed a cross-sectional 
retrospective study in a relatively low number of 
subjects, while a longitudinal placebo-controlled 
cross-over design would be much better to verify our 
working hypothesis. Nevertheless, we have limited 
our retrospective analysis to those without relevant 
coexistent diseases and receiving a standard 
guidelines-based medication in order to decrease 




subjects’ heterogeneity. Second, neither fasting nor 
postload insulin levels were measured and we were 
not able to calculate any indices of insulin resistance 
or β-cell responsiveness, which constrains 
mechanistic interpretation of the results. On the other 
hand, the magnitude of glycaemia is also of clinical 
importance in terms of prognostic predictive ability 
with regard to CV outcome. Finally, the information 
on PPI use prior to admission was self-reported, 
which could also pose a bias. 
Conclusions 
PPI use does not appear to be associated with 
altered glycaemia in subjects with CV disease. 
Unchanged glucose tolerance despite PPI usage may 
result from simultaneous activation of pathways that 
counteract the PPI-induced incretin-like effect. 
Further studies are warranted to explore putative 
novel pathways contributing to the net impact of PPIs 
on CV outcome.  
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